New York, NY. April 26, 2018. The Lupus Research Alliance today announced that the newly formed clinical affiliate Lupus Therapeutics will collaborate with the pharmaceutical company, Bristol-Myers Squibb (BMS), to conduct a global trial evaluating the novel investigational drug, BMS-986165, as a potential treatment for people with lupus.

BMS-986165 is a highly selective inhibitor of Tyrosine kinase 2 (Tyk2), which suppresses pathways that have been implicated in lupus.

Read full Press Release